Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct;12(10):647-654.
doi: 10.14740/jocmr4313. Epub 2020 Sep 21.

How Can Galectin-3 as a Biomarker of Fibrosis Improve Atrial Fibrillation Diagnosis and Prognosis?

Maria Mariana Barros Melo da Silveira  1   2 , Joao Victor Batista Cabral  1 , Bruno de Melo Souza  3 , Louis Hussein Patu Hazime  3 , Sara Larissa de Melo Araujo  4 , Amanda Tavares Xavier  3   5 , Edivaldo Bezerra Mendes Filho  1 , Luydson Richardson da Silva Vasconcelos  5 , Dario Celestino Sobral Filho  2   3 , Dinaldo Cavalcanti de Oliveira  1   2
Affiliations
Review

How Can Galectin-3 as a Biomarker of Fibrosis Improve Atrial Fibrillation Diagnosis and Prognosis?

Maria Mariana Barros Melo da Silveira et al. J Clin Med Res. 2020 Oct.

Abstract

Galectin-3 (Gal-3) is a biomarker of fibrosis that has been associated with atrial remodeling. Acknowledging the presence of a biomarker in patients with atrial fibrillation (AF) can allow for a better clinical treatment. The aim of this study was to assess the association of Gal-3 with atrial fibrosis in patients with AF. This is a systematic review study. From the total number of studies analyzed, 12 demonstrated a relation between atrial fibrosis and Gal-3 in patients with AF and presented statistically significant association values. We conclude that Gal-3 is associated with atrial fibrosis in patients with AF in all types, as well as after the arrhythmia treatment by ablation.

Keywords: Atrial fibrillation; Atrial fibrosis; Clinical studies; Experimental studies; Galectin-3; Observational studies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Potential mechanistic roles of galectin-3 in tissue fibrogenesis.
Figure 2
Figure 2
Results flowchart of studies search and selection strategy.
See this image and copyright information in PMC

References

    1. Pranata R, Yonas E, Chintya V, Tondas AE, Raharjo SB. Serum Galectin-3 level and recurrence of atrial fibrillation post-ablation - Systematic review and meta-analysis. Indian Pacing Electrophysiol J. 2020;20(2):64–69. doi: 10.1016/j.ipej.2020.02.002. - DOI - PMC - PubMed
    1. Magalhaes LP, Figueiredo MJO, Cintra FD, Saad EB, Kuniyoshi RR, Menezes Lorga Filho A, D'Avila ALB. et al. Executive summary of the II brazilian guidelines for atrial fibrillation. Arq Bras Cardiol. 2016;107(6):501–508. doi: 10.5935/abc.20160190. - DOI - PMC - PubMed
    1. Shen H, Wang J, Min J, Xi W, Gao Y, Yin L, Yu Y. et al. Activation of TGF-beta1/alpha-SMA/Col I Profibrotic Pathway in Fibroblasts by Galectin-3 Contributes to Atrial Fibrosis in Experimental Models and Patients. Cell Physiol Biochem. 2018;47(2):851–863. doi: 10.1159/000490077. - DOI - PubMed
    1. Nortamo S, Ukkola O, Lepojarvi S, Kentta T, Kiviniemi A, Junttila J, Huikuri H. et al. Association of sST2 and hs-CRP levels with new-onset atrial fibrillation in coronary artery disease. Int J Cardiol. 2017;248:173–178. doi: 10.1016/j.ijcard.2017.07.022. - DOI - PubMed
    1. Selcoki Y, Aydin HI, Celik TH, Isleyen A, Erayman A, Demircelik MB, Demirin H. et al. Galectin-3: A biochemical marker to detect paroxysmal atrial fibrillation? Clin Invest Med. 2016;39(6):27528. doi: 10.25011/cim.v39i6.27528. - DOI - PubMed

LinkOut - more resources